The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition
Open accessAbstract
Defective homologous recombination (HR) DNA repair imposed by BRCA1 or BRCA2 deficiency sensitizes cells to poly (ADP-ribose) polymerase (PARP)-1 inhibition and is currently exploited in clinical treatment of HR-deficient tumors. Here we show that mild hyperthermia (41–42.5 °C) induces degradation of BRCA2 and inhibits HR. We demonstrate that hyperthermia can be used to sensitize innately HR-proficient tumor cells to PARP-1 inhibitors and that this effect can be enhanced by heat shock protein inhibition. Our results, obtained from cell lines and in vivo tumor models, enable the design of unique therapeutic strategies involving localized on-demand induction of HR deficiency, an approach that we term induced synthetic lethality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N. J., Johnson, D. A., Richardson, T. B., Santarosa, M., Dillon, K. J., Hickson, I., Knights, C., et al. (2005) · Nature · doi:10.1038/nature03445 · Cited by 6,683
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
Bryant, H. E., Schultz, N., Thomas, H. D., Parker, K. M., Flower, D., Lopez, E., Kyle, S., Meuth, M., Curtin, N. J., & Helleday, T. (2005) · Nature · doi:10.1038/nature03443 · Cited by 5,198
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., Mortimer, P., Swaisland, H., Lau, A., O'Connor, M. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0900212 · Cited by 3,634
Self-citationMechanism of Eukaryotic Homologous Recombination
San Filippo, J., Sung, P., & Klein, H. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061306.125255 · Cited by 1,681
Proteasome inhibitors: valuable new tools for cell biologists.
Lee, D. H., & Goldberg, A. L. (1998) · Trends in Cell Biology · doi:10.1016/s0962-8924(98)01346-4 · Cited by 1,474
Human CtIP promotes DNA end resection
Sartori, A. A., Lukas, C., Coates, J., Mistrik, M., Fu, S., Bartek, J., Baer, R., Lukas, J., & Jackson, S. P. (2007) · Nature · doi:10.1038/nature06337 · Cited by 1,362 · cited 1×
“Early in HR, the ends of DSBs are resected in a reaction involving the MRE11/RAD50/NBS1, CtIP, and BRCA1 complexes (13, 14) generating single-stranded DNA stretches, which are subsequently coated by RPA (1).”
BackgroundSecondary mutations as a mechanism of cisplatin resistance in BRCA2-mutated cancers
Sakai, W., Swisher, E. M., Karlan, B. Y., Agarwal, M. K., Higgins, J., Friedman, C., Villegas, E., Jacquemont, C., Farrugia, D. J., Couch, F. J., et al. (2008) · Nature · doi:10.1038/nature06633 · Cited by 1,086
Resistance to therapy caused by intragenic deletion in BRCA2
Edwards, S. L., Brough, R., Lord, C. J., Natrajan, R., Vatcheva, R., Levine, D. A., Boyd, J., Reis-Filho, J. S., & Ashworth, A. (2008) · Nature · doi:10.1038/nature06548 · Cited by 1,011 · cited 1×
“Moreover, because our approach is not based on genetic deficiency, as is the case in hereditary BRCA2-deficient tumors, it is not likely that a previously described mechanism of resistance to the inhibitor will be relevant (37, 38).”
BackgroundThe MRE11 complex: at the crossroads of DNA repair and checkpoint signalling
D'Amours, D., & Jackson, S. P. (2002) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm805 · Cited by 874 · cited 1×
“Early in HR, the ends of DSBs are resected in a reaction involving the MRE11/RAD50/NBS1, CtIP, and BRCA1 complexes (13, 14) generating single-stranded DNA stretches, which are subsequently coated by RPA (1).”
BackgroundMechanism of homologous recombination from the RecA–ssDNA/dsDNA structures
Chen, Z., Yang, H., & Pavletich, N. P. (2008) · Nature · doi:10.1038/nature06971 · Cited by 728
Issels, R. D., Lindner, L. H., Verweij, J., Wust, P., Reichardt, P., Schem, B.-C., Abdel-Rahman, S., Daugaard, S., Salat, C., Wendtner, C.-M., et al. (2010) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70071-1 · Cited by 659
Spatial organization of the mammalian genome surveillance machinery in response to DNA strand breaks
Bekker-Jensen, S., Lukas, C., Kitagawa, R., Melander, F., Kastan, M. B., Bartek, J., & Lukas, J. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200510130 · Cited by 625
BRCA2 is required for ionizing radiation-induced assembly of Rad51 complex in vivo.
Yuan, S. F., Lee, S. Y., Chen, G., Song, M., Tomlinson, G. E., & Lee, E. Y.-H. P. (1999) · PubMed · Cited by 474
Disruption of Mouse RAD54 Reduces Ionizing Radiation Resistance and Homologous Recombination
Essers, J., Hendriks, R. W., Swagemakers, S. M. A., Troelstra, C., de Wit, J., Bootsma, D., Hoeijmakers, J. H. J., & Kanaar, R. (1997) · Cell · doi:10.1016/s0092-8674(00)80199-3 · Cited by 434
Self-citationSister Chromatid Exchanges Are Mediated by Homologous Recombination in Vertebrate Cells
Sonoda, E., Sasaki, M. S., Morrison, C., Yamaguchi-Iwai, Y., Takata, M., & Takeda, S. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.7.5166 · Cited by 426
The endless tale of non-homologous end-joining
Weterings, E., & Chen, D. J. (2008) · Cell Research · doi:10.1038/cr.2008.3 · Cited by 418
Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., Curtin, N., Boddy, A., McHugh, P., Newell, D., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1223 · Cited by 383
Homologous repair of DNA damage and tumorigenesis:the BRCA connection
Jasin, M. (2002) · Oncogene · doi:10.1038/sj.onc.1206176 · Cited by 361
Modi, S., Stopeck, A. T., Gordon, M. S., Mendelson, D., Solit, D. B., Bagatell, R., Ma, W., Wheler, J., Rosen, N., Norton, L., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.7960 · Cited by 335
Hyperthermic radiosensitization: mode of action and clinical relevance
KAMPINGA, H. H., & DIKOMEY, E. (2001) · International Journal of Radiation Biology · doi:10.1080/09553000010024687 · Cited by 259
Experimental radiotherapy of a rat rhabdomyosarcoma with 15 MeV neutrons and 300 kV X-rays
Barendsen, G. W., & Broerse, J. J. (1970) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(70)90006-x · Cited by 255
Nuclear dynamics of RAD52 group homologous recombination proteins in response to DNA damage
Essers, J. (2002) · The EMBO Journal · doi:10.1093/emboj/21.8.2030 · Cited by 251
Self-citationExperimental radiotherapy of a rat rhabdomyosarcoma with 15 MeV neutrons and 300 kV X-rays
Barendsen, G. W., & Broerse, J. J. (1969) · European Journal of Cancer (1965) · doi:10.1016/0014-2964(69)90051-6 · Cited by 183
Koziol, J. A., Maxwell, D. A., Fukushima, M., Colmerauer, M. E. M., & Pilch, Y. H. (1981) · Biometrics · doi:10.2307/2530427 · Cited by 169
BRCA2: a universal recombinase regulator
Thorslund, T., & West, S. C. (2007) · Oncogene · doi:10.1038/sj.onc.1210870 · Cited by 161
Inhibition of Hsp90 Compromises the DNA Damage Response to Radiation
Dote, H., Burgan, W. E., Camphausen, K., & Tofilon, P. J. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2181 · Cited by 160
Quax, P. H. A., van Muijen, G. N. P., Weening-Verhoeff, E. J., Lund, L. R., Danø, K., Ruiter, D. J., & Verheijen, J. H. (1991) · The Journal of Cell Biology · doi:10.1083/jcb.115.1.191 · Cited by 155
Targeted cancer therapies based on the inhibition of DNA strand break repair
O’Connor, M. J., Martin, N. M. B., & Smith, G. C. M. (2007) · Oncogene · doi:10.1038/sj.onc.1210879 · Cited by 155
Self-citationJäger, M., Dronkert, M. L., Modesti, M., Beerens, C. E., Kanaar, R., & van Gent, D. C. (2001) · Nucleic Acids Research · doi:10.1093/nar/29.6.1317 · Cited by 152
Self-citationBowman, K. J., Newell, D. R., Calvert, H., & Curtin, N. J. (2001) · British Journal of Cancer · doi:10.1054/bjoc.2000.1555 · Cited by 144
Modesti, M., Budzowska, M., Baldeyron, C., Demmers, J., Ghirlando, R., & Kanaar, R. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.08.025 · Cited by 136
Self-citationNoguchi, M., Yu, D. S., Hirayama, R., Ninomiya, Y., Sekine, E., Kubota, N., Andō, K., & Okayasu, R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.10.094 · Cited by 136
Recombination Mediator and Rad51 Targeting Activities of a Human BRCA2 Polypeptide
Filippo, J. S., Chi, P., Sehorn, M. G., Etchin, J., Krejci, L., & Sung, P. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m601249200 · Cited by 134 · cited 1×
“loading of RAD51 on the proper DNA substrate (17, 18) and the accumulation of RAD51 in IRIF (19, 20).”
BackgroundKampinga, H. H., Dynlacht, J. R., & Dikomey, E. (2004) · International Journal of Hyperthermia · doi:10.1080/02656730310001627713 · Cited by 100
Analysis of mouse Rad54 expression and its implications for homologous recombination
Essers, J., Hendriks, R. W., Wesoły, J., Beerens, C. E. M. T., Smit, B., Hoeijmakers, J. H. J., Wyman, C., Dronkert, M. L. G., & Kanaar, R. (2002) · DNA repair · doi:10.1016/s1568-7864(02)00110-6 · Cited by 97
Self-citationIliakis, G. E., Wu, W., & Wang, M. (2008) · International Journal of Hyperthermia · doi:10.1080/02656730701784782 · Cited by 71
Detection of sister chromatid exchanges by 4?-6-diamidino-2-phenylindole fluorescence
Lin, M. S., & Alfi, O. S. (1976) · Chromosoma · doi:10.1007/bf00295208 · Cited by 69
Budzowska, M., Jaspers-Dekker, I., Essers, J., de Waard, H., van Drunen, E., Hanada, K., Beverloo, B., Hendriks, R. W., de Klein, A., Kanaar, R., et al. (2004) · The EMBO Journal · doi:10.1038/sj.emboj.7600353 · Cited by 62
Self-citationInduction of linear tracks of DNA double-strand breaks by α-particle irradiation of cells
Stap, J., Krawczyk, P. M., van Oven, C. H., Barendsen, G. W., Essers, J., Kanaar, R., & Aten, J. A. (2008) · Nature Methods · doi:10.1038/nmeth.f.206 · Cited by 59
Self-citationMathieu, J., Flexor, M., Lanotte, M., & Besançon, F. (2007) · Oncogene · doi:10.1038/sj.onc.1210997 · Cited by 20
Evaluation of Recombination Repair Pathways in Thermal Radiosensitization
Raaphorst, G., Maude-Leblanc, J., & Li, L. (2004) · Radiation Research · doi:10.1667/rr3103 · Cited by 11
Cited by
DNA repair dysregulation from cancer driver to therapeutic target
Curtin, N. J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3399 · Cited by 1,051
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Datta, N. R., Ordóñez, S. G., Gaipl, U. S., Paulides, M. M., Crezee, H., Gellermann, J., Marder, D., Puric, E., & Bodis, S. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.009 · Cited by 588
Understanding and overcoming resistance to PARP inhibitors in cancer therapy
Dias, M. P., Moser, S. C., Ganesan, S., & Jonkers, J. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00532-x · Cited by 505
The diverse roles and clinical relevance of PARPs in DNA damage repair: Current state of the art
De Vos, M., Schreiber, V., & Dantzer, F. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.03.018 · Cited by 492
Metadata
- Authors
- Krawczyk, P. M., Eppink, B., Essers, J., Stap, J., Rodermond, H., Odijk, H., Zelensky, A., van Bree, C., Stalpers, L. J., Buist, M. R., Soullié, T., Rens, J., Verhagen, H. J. M., O'Connor, M. J., Franken, N. A. P., ten Hagen, T. L. M., Kanaar, R., & Aten, J. A.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2011-05-09
- Volume
- 108
- Issue
- 24
- Pages
- 9851-9856
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2162919209
- Cited by
- 349
- References
- 41
- FWCI
- 7.86
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.